EP4324917A4 - Cell bank composed of ips cells for introducing t cell receptor gene - Google Patents

Cell bank composed of ips cells for introducing t cell receptor gene

Info

Publication number
EP4324917A4
EP4324917A4 EP22788071.3A EP22788071A EP4324917A4 EP 4324917 A4 EP4324917 A4 EP 4324917A4 EP 22788071 A EP22788071 A EP 22788071A EP 4324917 A4 EP4324917 A4 EP 4324917A4
Authority
EP
European Patent Office
Prior art keywords
cell
introduction
ips cells
receptor gene
bank
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP22788071.3A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP4324917A1 (en
Inventor
Ryosuke GONOTSUBO
Mitsujiro Osawa
Yasumichi Hitoshi
Shin Kaneko
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thyas Co Ltd
Original Assignee
Thyas Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thyas Co Ltd filed Critical Thyas Co Ltd
Publication of EP4324917A1 publication Critical patent/EP4324917A1/en
Publication of EP4324917A4 publication Critical patent/EP4324917A4/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4201—Neoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A61K40/4243—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4261—Proteoglycans, e.g. glypican, brevican or CSPG4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1082—Preparation or screening gene libraries by chromosomal integration of polynucleotide sequences, HR-, site-specific-recombination, transposons, viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18811—Sendai virus
    • C12N2760/18841—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18843—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP22788071.3A 2021-04-16 2022-03-31 Cell bank composed of ips cells for introducing t cell receptor gene Pending EP4324917A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021069972 2021-04-16
PCT/JP2022/016392 WO2022220146A1 (ja) 2021-04-16 2022-03-31 Ｔ細胞受容体遺伝子を導入するためのｉＰＳ細胞により構成される細胞バンク

Publications (2)

Publication Number Publication Date
EP4324917A1 EP4324917A1 (en) 2024-02-21
EP4324917A4 true EP4324917A4 (en) 2025-04-16

Family

ID=83639671

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22788071.3A Pending EP4324917A4 (en) 2021-04-16 2022-03-31 Cell bank composed of ips cells for introducing t cell receptor gene

Country Status (7)

Country Link
US (1) US20250177524A1 (https=)
EP (1) EP4324917A4 (https=)
JP (1) JPWO2022220146A1 (https=)
CN (1) CN117157391A (https=)
AU (1) AU2022259170A1 (https=)
CA (1) CA3213440A1 (https=)
WO (1) WO2022220146A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022059780A1 (ja) * 2020-09-18 2022-03-24 サイアス株式会社 ｉＰＳ細胞を介する再生Ｔ細胞の製造方法
JPWO2023249071A1 (https=) * 2022-06-24 2023-12-28

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014165707A2 (en) * 2013-04-03 2014-10-09 Memorial Sloan-Kettering Cancer Center Effective generation of tumor-targeted t-cells derived from pluripotent stem cells
WO2016010154A1 (ja) * 2014-07-18 2016-01-21 宏 河本 抗原特異的ｔ細胞受容体遺伝子を有する多能性幹細胞の製造方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2011096482A1 (ja) 2010-02-03 2013-06-13 国立大学法人 東京大学 多能性幹細胞を用いた免疫機能再建法
EP2853590B1 (en) 2012-05-22 2018-11-07 The University of Tokyo Method for producing antigen-specific t cells
KR102654784B1 (ko) * 2014-07-18 2024-04-04 사이아스 가부시키가이샤 다능성 줄기세포로부터 세포-기반 면역요법용 t 세포를 유도하는 방법
ES2886631T3 (es) * 2016-04-15 2021-12-20 Univ Kyoto Método para inducir células T positivas para CD8 específicas de antígeno
TW201835100A (zh) * 2017-02-06 2018-10-01 國立研究開發法人國立癌症研究中心 新穎ｔ細胞受體
CN112534044A (zh) * 2018-02-16 2021-03-19 凯德药业股份有限公司 经修饰的多能干细胞及制备和使用方法
CN112752838A (zh) * 2018-07-26 2021-05-04 国立大学法人京都大学 制备引入外源抗原受体的细胞的方法
EP3831936A4 (en) * 2018-07-31 2022-04-13 Thyas Co. Ltd. METHOD FOR PRODUCING A REGENERATED T LYMPHOCYTE POPULATION USING IPS CELLS
AU2020393334A1 (en) * 2019-11-25 2022-06-16 Kyoto University T-cell master cell bank
WO2022059780A1 (ja) * 2020-09-18 2022-03-24 サイアス株式会社 ｉＰＳ細胞を介する再生Ｔ細胞の製造方法
JPWO2022145490A1 (https=) * 2021-01-04 2022-07-07

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014165707A2 (en) * 2013-04-03 2014-10-09 Memorial Sloan-Kettering Cancer Center Effective generation of tumor-targeted t-cells derived from pluripotent stem cells
WO2016010154A1 (ja) * 2014-07-18 2016-01-21 宏 河本 抗原特異的ｔ細胞受容体遺伝子を有する多能性幹細胞の製造方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
IRIGUCHI SHOICHI ET AL: "A clinically applicable and scalable method to regenerate T-cells from iPSCs for off-the-shelf T-cell immunotherapy", vol. 12, no. 1, 18 January 2021 (2021-01-18), XP093007406, Retrieved from the Internet <URL:https://www.nature.com/articles/s41467-020-20658-3> [retrieved on 20221212], DOI: 10.1038/s41467-020-20658-3 *
MAEDA TAKUYA ET AL: "Regeneration of Tumor-Antigen-Specific Cytotoxic T Lymphocytes from iPSCs Transduced with Exogenous TCR Genes", vol. 19, 1 December 2020 (2020-12-01), GB, pages 250 - 260, XP055905953, ISSN: 2329-0501, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7566080/pdf/main.pdf> [retrieved on 20220328], DOI: 10.1016/j.omtm.2020.09.011 *
See also references of WO2022220146A1 *

Also Published As

Publication number Publication date
CN117157391A (zh) 2023-12-01
AU2022259170A1 (en) 2023-10-12
JPWO2022220146A1 (https=) 2022-10-20
CA3213440A1 (en) 2022-10-20
EP4324917A1 (en) 2024-02-21
WO2022220146A1 (ja) 2022-10-20
US20250177524A1 (en) 2025-06-05

Similar Documents

Publication Publication Date Title
GB201020995D0 (en) Biological materials and uses thereof
MX2013008375A (es) Anticuerpos anti proteina accesoria del receptor de interleucina-1 y su uso para tratamiento en humanos.
EA201891212A1 (ru) Адресная дезорганизация клеточного рецептора гкгс
PL3287525T3 (pl) Preparaty RNA zawierające oczyszczony zmodyfikowany RNA do przeprogramowywania komórek
BR112016017808A8 (pt) composto ou sal farmaceuticamente aceitável, uso de um composto e composição para a inibição de um efeito betaamilóide numa célula neuronal
EP2612911A4 (en) COMPOSITION FOR THE INDUCTION OF PLURIPOTENTER STEM CELLS AND THEIR USE
RU2012122025A (ru) Плюрипотентные стволовые клетки
EP2291659A4 (en) SMALL CHIMERIC MOLECULES FOR THE RECRUITMENT OF ANTIBODIES TO CANCER CELLS
DE602008003645D1 (de) Elektrolytmembran für Brennstoffzelle und Brennstoffzelle enthaltend diesselbe
DK2574677T3 (da) Fremgangsmåder til celledyrkning
EP4324917A4 (en) Cell bank composed of ips cells for introducing t cell receptor gene
PL2613801T3 (pl) Zastosowanie komórek T pamięci centralnych przeciwko obcym antygenom do leczenia białaczki/chłoniaka
EP3601543A4 (en) ADDING NUCLEASES DIRECTLY TO CELL CULTURE TO FACILITATE DIGESTION AND RELEASE OF HOST CELL NUCLEIC ACIDS
EP2601314A4 (en) PROGNOSTIC SIGNATURES FOR NON-SMALL LUNG CANCER
EP3433397A4 (en) ELECTRODE CONFIGURATIONS FOR ELECTROLYTIC CELLS AND RELATED METHODS
TR201909747T4 (tr) Aktarım.
EP2383334A4 (en) FEEDER CELL FOR TARGET CELL INDUCTION
TR201905632T4 (tr) Bir tümörün tedavisinde kullanıma yönelik preeklamptik plasental mezenkimal kök hücre koşullu ortam.
BR112012008436A2 (pt) eletrodo catódico, célula eletroquimica e seus usos
BR112014020756A2 (pt) co-uso de um inibidor da clusterina com um inibidor do egfr para tratar o câncer
EP3475412A4 (en) CELL CULTURE CONTAINER
DE602008003789D1 (de) Elektrode für membranelektrolysezellen
EP2716598A4 (en) HYDROGEN GENERATOR AND FUEL CELL SYSTEM
EP3531486A4 (en) HYDROGEN STORAGE UNIT AND FUEL CELL SYSTEM
EP2703340A4 (en) HYDROGEN GENERATOR AND FUEL CELL SYSTEM

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230929

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20250318

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/90 20060101ALI20250312BHEP

Ipc: C12N 5/0783 20100101ALI20250312BHEP

Ipc: C07K 14/725 20060101ALI20250312BHEP

Ipc: A61K 40/46 20250101ALI20250312BHEP

Ipc: A61K 40/42 20250101ALI20250312BHEP

Ipc: A61K 40/32 20250101ALI20250312BHEP

Ipc: A61K 40/11 20250101ALI20250312BHEP

Ipc: C12P 21/08 20060101ALI20250312BHEP

Ipc: C12N 15/86 20060101ALI20250312BHEP

Ipc: C12N 15/85 20060101ALI20250312BHEP

Ipc: C12N 15/62 20060101ALI20250312BHEP

Ipc: C12N 15/13 20060101ALI20250312BHEP

Ipc: C12N 15/09 20060101ALI20250312BHEP

Ipc: C07K 19/00 20060101ALI20250312BHEP

Ipc: C07K 16/46 20060101ALI20250312BHEP

Ipc: C07K 16/28 20060101ALI20250312BHEP

Ipc: C07K 16/18 20060101ALI20250312BHEP

Ipc: C07K 16/10 20060101ALI20250312BHEP

Ipc: A61P 35/00 20060101ALI20250312BHEP

Ipc: A61K 35/17 20150101ALI20250312BHEP

Ipc: C12N 5/10 20060101AFI20250312BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20260202